NKGen Biotech Inc (NKGN)

Currency in USD
0.0020
+0.0010(+100.00%)
Closed·
NKGN Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
NKGN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.00200.2000
52 wk Range
0.00020.9649
Key Statistics
Prev. Close
0.001
Open
0.002
Day's Range
0.002-0.2
52 wk Range
0.0002-0.9649
Volume
11.35K
Average Volume (3m)
37.35K
1-Year Change
-99.66%
Book Value / Share
-1.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NKGN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Significant return over the last week

NKGen Biotech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Sell

NKGen Biotech Inc Company Profile

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company’s autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.

Compare NKGN to Peers and Sector

Metrics to compare
NKGN
Peers
Sector
Relationship
P/E Ratio
0.0x−2.9x−0.7x
PEG Ratio
0.000.030.00
Price/Book
0.0x2.4x2.6x
Price / LTM Sales
-128.7x3.4x
Upside (Analyst Target)
-124.9%38.0%
Fair Value Upside
Unlock14.5%5.3%Unlock

Earnings

Latest Release
Oct 08, 2025
EPS / Forecast
-0.74 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NKGN Income Statement

People Also Watch

1.670
OVID
-4.02%
181.47
KRYS
-3.86%
26.11
CLPT
-9.84%
66.23
PTCT
+0.33%
8.570
VSTM
-7.25%

FAQ

What Stock Exchange Does NKGen Biotech Trade On?

NKGen Biotech is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for NKGen Biotech?

The stock symbol for NKGen Biotech is "NKGN."

What Is the NKGen Biotech Market Cap?

As of today, NKGen Biotech market cap is 248.75K.

What Is NKGen Biotech's Earnings Per Share (TTM)?

The NKGen Biotech EPS (TTM) is -1.54.

From a Technical Analysis Perspective, Is NKGN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has NKGen Biotech Stock Split?

NKGen Biotech has split 0 times.

How Many Employees Does NKGen Biotech Have?

NKGen Biotech has 26 employees.

What is the current trading status of NKGen Biotech (NKGN)?

As of 11 Oct 2025, NKGen Biotech (NKGN) is trading at a price of 0.0020, with a previous close of 0.00. The stock has fluctuated within a day range of 0.0020 to 0.2000, while its 52-week range spans from 0.0002 to 0.9649.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.